JP7833044B2 - タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法 - Google Patents

タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Info

Publication number
JP7833044B2
JP7833044B2 JP2024543113A JP2024543113A JP7833044B2 JP 7833044 B2 JP7833044 B2 JP 7833044B2 JP 2024543113 A JP2024543113 A JP 2024543113A JP 2024543113 A JP2024543113 A JP 2024543113A JP 7833044 B2 JP7833044 B2 JP 7833044B2
Authority
JP
Japan
Prior art keywords
lpa
dsrna
disease
present
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024543113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504863A5 (enExample
JP2025504863A (ja
Inventor
シュ，ドンシュ
パトリック シャオ，ペンチェン
シャ，シウェイ
Original Assignee
シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド filed Critical シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド
Publication of JP2025504863A publication Critical patent/JP2025504863A/ja
Publication of JP2025504863A5 publication Critical patent/JP2025504863A5/ja
Priority to JP2026036105A priority Critical patent/JP2026116903A/ja
Application granted granted Critical
Publication of JP7833044B2 publication Critical patent/JP7833044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024543113A 2022-01-24 2023-01-23 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法 Active JP7833044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026036105A JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022073415 2022-01-24
CNPCT/CN2022/073415 2022-01-24
PCT/CN2023/073456 WO2023138689A1 (zh) 2022-01-24 2023-01-23 抑制LPA(Apo(a))蛋白表达的组合物和方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026036105A Division JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2025504863A JP2025504863A (ja) 2025-02-19
JP2025504863A5 JP2025504863A5 (enExample) 2025-10-21
JP7833044B2 true JP7833044B2 (ja) 2026-03-18

Family

ID=87347910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024543113A Active JP7833044B2 (ja) 2022-01-24 2023-01-23 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法
JP2026036105A Pending JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026036105A Pending JP2026116903A (ja) 2022-01-24 2026-03-06 タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法

Country Status (16)

Country Link
US (2) US20250297250A1 (enExample)
EP (1) EP4471144A4 (enExample)
JP (2) JP7833044B2 (enExample)
KR (1) KR20240135657A (enExample)
CN (1) CN118679259A (enExample)
AU (1) AU2023210010A1 (enExample)
CA (1) CA3248387A1 (enExample)
CL (1) CL2024002168A1 (enExample)
CO (1) CO2024009492A2 (enExample)
DO (1) DOP2024000141A (enExample)
IL (1) IL314060A (enExample)
JO (1) JOP20240159A1 (enExample)
MX (1) MX2024008989A (enExample)
PE (1) PE20250779A1 (enExample)
TW (1) TW202345865A (enExample)
WO (1) WO2023138689A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
AU2023404700A1 (en) * 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
CN119506275A (zh) * 2023-08-22 2025-02-25 苏州炫景生物科技有限公司 抑制lpa基因表达的双链寡核苷酸及其应用
UY40897A (es) * 2023-09-21 2025-03-31 Ionis Pharmaceuticals Inc Compuestos y métodos para inhibir lpa
WO2025082059A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 经修饰的dsRNA、双链RNAi剂及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN122514601A (zh) * 2023-11-29 2026-08-04 美国圣因生物股份有限公司 靶向Lp(a)的小干扰RNA及其用途
TW202546233A (zh) * 2024-02-05 2025-12-01 美商靖因藥業（上海）有限公司 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途
WO2025252159A1 (zh) * 2024-06-06 2025-12-11 大睿生物医药科技(上海)有限公司 调控LPA表达的dsRNA分子
WO2026026890A1 (zh) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 用于抑制LPA基因表达的siRNA及其修饰物与应用
WO2026092650A1 (zh) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 一种抑制LPA基因表达的RNAi制剂及其应用
WO2026131490A1 (en) * 2024-12-20 2026-06-25 Ribocure Pharmaceuticals Ab Oligonucleotide, oligonucleotide conjugate and composition, and use thereof
WO2026133253A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507499A (ja) 2005-09-15 2009-02-26 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の抑制のためのｒｎａアンタゴニスト化合物
JP2015522255A (ja) 2012-05-24 2015-08-06 アイシス ファーマシューティカルズ， インコーポレーテッド アポリポタンパク質（ａ）発現を調節するための方法および組成物
JP2016522817A (ja) 2013-05-01 2016-08-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アポリポタンパク質（ａ）発現を調節するための組成物および方法
WO2019092283A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2020099476A1 (en) 2018-11-13 2020-05-22 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2020533334A (ja) 2017-09-11 2020-11-19 アローヘッド ファーマシューティカルズ インコーポレイテッド アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
WO2021119034A1 (en) 2019-12-09 2021-06-17 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
WO2022079221A1 (en) 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
WO2023041079A1 (zh) 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101292034A (zh) * 2005-09-15 2008-10-22 桑塔里斯制药公司 抑制apo-b100表达的rna拮抗化合物
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
WO2024035898A2 (en) * 2022-08-11 2024-02-15 Sirius Therapeutics, Inc. Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507499A (ja) 2005-09-15 2009-02-26 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の抑制のためのｒｎａアンタゴニスト化合物
JP2015522255A (ja) 2012-05-24 2015-08-06 アイシス ファーマシューティカルズ， インコーポレーテッド アポリポタンパク質（ａ）発現を調節するための方法および組成物
JP2016522817A (ja) 2013-05-01 2016-08-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アポリポタンパク質（ａ）発現を調節するための組成物および方法
JP2020533334A (ja) 2017-09-11 2020-11-19 アローヘッド ファーマシューティカルズ インコーポレイテッド アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
WO2019092283A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2020099476A1 (en) 2018-11-13 2020-05-22 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2021119034A1 (en) 2019-12-09 2021-06-17 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
WO2022079221A1 (en) 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途

Also Published As

Publication number Publication date
KR20240135657A (ko) 2024-09-11
TW202345865A (zh) 2023-12-01
DOP2024000141A (es) 2024-10-15
PE20250779A1 (es) 2025-03-14
EP4471144A4 (en) 2026-01-21
US20250257356A1 (en) 2025-08-14
IL314060A (en) 2024-09-01
JOP20240159A1 (ar) 2024-07-21
CL2024002168A1 (es) 2025-01-10
MX2024008989A (es) 2024-07-29
CN118679259A (zh) 2024-09-20
CO2024009492A2 (es) 2024-10-31
EP4471144A1 (en) 2024-12-04
CA3248387A1 (en) 2025-07-09
US20250297250A1 (en) 2025-09-25
WO2023138689A1 (zh) 2023-07-27
AU2023210010A1 (en) 2024-07-25
JP2026116903A (ja) 2026-07-14
JP2025504863A (ja) 2025-02-19

Similar Documents

Publication Publication Date Title
EP4471144A1 (en) Composition and method for inhibiting expression of protein lpa(apo(a))
JP7829035B2 (ja) アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法
TWI877520B (zh) 用於抑制血管生成素樣３（ａｎｇｐｔｌ３）蛋白表達的組合物和方法
US20240158790A1 (en) Chimeric double-stranded nucleic acid
JP2025531313A (ja) 特定の修飾ＲＮＡｉ試薬及び組成物
JP2024541559A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）タンパク質の発現を阻害するための組成物および方法
TW202404615A (zh) 用於抑制黃嘌呤脫氫酶(xdh)的組合物和方法
JP2026510329A (ja) 細胞死を誘導するｄｆｆａ様エフェクターｂ（ｃｉｄｅｂ）発現を抑制するための組成物及び方法
TW202525307A (zh) 抑制抑制素亞基βE（INHBE）的表達的組合物和方法
CN122003498A (zh) 抑制淀粉样前体蛋白(app)表达的组合物和方法
KR20260030856A (ko) 보체 인자 b(cfb) 발현을 억제하기 위한 조성물 및 방법
TW202346586A (zh) 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法
RU2854980C2 (ru) Композиции и способы ингибирования экспрессии ангиопоэтин-подобного белка 3 (angptl3)
HK40116126A (en) Composition and method for inhibiting expression of protein lpa(apo(a))
HK40096008A (en) Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) protein
HK40109544A (en) Compositions and methods for inhibiting expression of prekallikrein (pkk) protein
HK40130333A (zh) 用於抑制pd-l1表达的组合物和方法
HK40115058A (en) Composition and method for inhibiting angiotensinogen (agt) protein expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7833044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150